Biopharmaceutical company Soligenix, Inc. has appointed Oreola Donini as its new senior vice president and chief scientific officer, the company announced Wednesday.
The company specializes in producing products for medical needs that are currently unmet in the areas of oncology, inflammation and bio defense. Donini joined the company in August 2013 as the vice president of Preclinical Research and Development. Prior to joining Soilgenix, Donini spent 15 years working in the biomedical field, where she has been heavily involved with drug discovery, biotechnology start-ups and has been an integral part of early stage development of new therapies.
She has successfully led many of the company's projects that were granted federal funding for biodefense mechanismsunder the National Institute of Allergy and Infectious Disease (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA.)
She earned her Ph.D. from Queen's University in Kingston, Ontario, Canada and she has completed post-doctoral research with the University of California-San Francisco.
Christopher Schaber, president and CEO of Soligenix, stated that the company was proud to appoint Donini.
"Her extensive experience in the areas of inflammation, infectious disease, tissue damage and innate immunity will be instrumental to us as we continue to advance our multiple development programs,” Schaber said.